Mizuho Securities Reaffirm Bullish Stance on Surgery Partners (SGRY)

Core Viewpoint - Surgery Partners (NASDAQ:SGRY) is identified as a promising mid-cap healthcare stock with a current price target of $19, indicating a potential upside of 21% from its current trading level [1]. Group 1: Analyst Ratings and Forecasts - Mizuho Securities analyst Ann Hynes has reiterated a Buy rating on Surgery Partners, supported by a positive forecast for managed care and health facilities in 2026, which is expected to improve margins, particularly in Medicaid and Medicare [2]. - As of December 19, Surgery Partners has coverage from 11 analysts, with 8 assigning a Buy rating and 3 a Hold rating. The stock has an estimated upside potential of 67.5% from current levels, with a consensus target price of $26.30 [3]. Group 2: Company Overview - Surgery Partners provides surgical and ancillary services across various locations in the United States, focusing on non-emergency surgical procedures such as orthopedics, ophthalmology, and pain management, through both single- and multi-specialty facilities [4].